Vertex Expects Shorter Duration Of Therapy Will Give Telaprevir Long Reign Atop Market
This article was originally published in The Pink Sheet Daily
Executive Summary
With high SVR rate and quad therapy showing potential for 12-week treatment period, telaprevir may enjoy short- and long-term market success.
You may also be interested in...
EASL Preview: Dual Versus Quad Combinations
Data on oral hepatitis C drugs from Pharmasset, Gilead, Vertex, Bristol-Myers and others will be watched closely at the EASL International Liver Congress.
EASL Preview: Dual Versus Quad Combinations
Data on oral hepatitis C drugs from Pharmasset, Gilead, Vertex, Bristol-Myers and others will be watched closely at the EASL International Liver Congress.
Vertex And Merck Neck-To-Neck In HCV Race
Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.